Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,796.00
Bid: 1,796.00
Ask: 1,796.50
Change: 7.50 (0.42%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,792.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
15th Jan 20214:00 pmRNSDirector/PDMR Shareholding
15th Jan 20213:14 pmRNSDirector/PDMR Shareholding
13th Jan 20211:45 pmRNSDirector/PDMR Shareholding
11th Jan 202111:05 amRNSDirector/PDMR Shareholding
11th Jan 20219:16 amRNSDirector/PDMR Shareholding
4th Jan 202111:25 amRNSTotal Voting Rights
30th Dec 202011:52 amRNSDirector/PDMR Shareholding
23rd Dec 20202:44 pmRNSDirector/PDMR Shareholding
21st Dec 20207:00 amRNSViiV first long-acting HIV regimen approved in EU
11th Dec 20207:00 amRNSSanofi/ GSK update on COVID vaccine candidate
10th Dec 20205:51 pmRNSDirector/PDMR Shareholding
10th Dec 202011:55 amRNSBlock Listing Application
9th Dec 20203:04 pmRNSDirector/PDMR Shareholding
3rd Dec 20205:53 pmRNSDirector/PDMR Shareholding
1st Dec 20203:00 pmRNSTotal Voting Rights
27th Nov 20202:58 pmRNSGSK publishes provisional 2021 dividend dates
26th Nov 202012:35 pmRNSEMTN Supplementary Prospectus
25th Nov 202010:26 amRNSDirector/PDMR Shareholding
23rd Nov 20208:59 amRNSBlock listing Interim Review
19th Nov 20205:40 pmRNSHolding(s) in Company
17th Nov 20205:48 pmRNSDirector/PDMR Shareholding
12th Nov 20201:00 pmRNSMedicago GSK phase 2/3 study start
11th Nov 20203:08 pmRNSDirector/PDMR Shareholding
11th Nov 202011:13 amRNSDirector/PDMR Shareholding
9th Nov 20207:00 amRNSViiV’s cabotegravir superior for HIV prevention
4th Nov 20205:32 pmRNSDirector/PDMR Shareholding
4th Nov 20204:45 pmRNSDirector/PDMR Shareholding
3rd Nov 20204:09 pmRNSDirector/PDMR Shareholding
3rd Nov 20208:00 amRNSGSK sets new environmental goals
2nd Nov 20205:16 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:59 pmRNSTotal Voting Rights
30th Oct 20205:08 pmRNSHolding(s) in Company
30th Oct 202012:53 pmRNSDirector/PDMR Shareholding
28th Oct 20205:46 pmRNSDirector/PDMR Shareholding
28th Oct 202012:00 pmRNS3rd Quarter Results
28th Oct 20207:00 amRNSSanofi and GSK support COVAX - 200m vaccine doses
22nd Oct 202012:34 pmRNSHolding(s) in Company
16th Oct 202012:18 pmRNSPositive CHMP opinion ViiV long-acting HIV regimen
14th Oct 20203:30 pmRNSDirector/PDMR Shareholding
14th Oct 20203:29 pmRNSDirector/PDMR Shareholding
13th Oct 20202:41 pmRNSDirector/PDMR Shareholding
13th Oct 20202:08 pmRNSDirector/PDMR Shareholding
13th Oct 20202:01 pmRNSDirector/PDMR Shareholding
13th Oct 20201:55 pmRNSDirector/PDMR Shareholding
13th Oct 20201:49 pmRNSDirector/PDMR Shareholding
1st Oct 20204:30 pmRNSTotal Voting Rights
22nd Sep 20205:42 pmRNSSanofi/GSK agree up to 72m Canada COVID doses
11th Sep 20203:17 pmRNSDirector/PDMR Shareholding
10th Sep 202010:01 amRNSDirector/PDMR Shareholding
9th Sep 20203:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.